MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$2,483K
Net Income
-$10,490K
Net Profit Margin
-422.47%
EPS
-$0.26
Unit: Thousand (K) dollars
Revenue Breakdown
    • Recurring Non Capital
    • Capital Equipment
Revenue Breakdown
    • US
    • CA
    • DE
Revenue Breakdown
    • Transferred At Point In Time
    • Transferred Over Time
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue (note 12)
2,483
5,337
5,977
5,289
Cost of sales
536
1,505
1,986
1,358
Gross profit
1,947
3,832
3,991
3,931
Research and development
5,654
5,262
4,272
5,418
Selling, general and administrative
7,359
6,591
7,088
7,426
Total operating expenses
13,013
11,853
11,360
12,844
Operating loss
-11,066
-8,021
-7,369
-8,913
Net finance income
336
377
160
122
Net foreign exchange (gain) loss
1,245
616
-939
935
Total other (income) expenses
1,581
993
-779
1,057
Net loss before income taxes
-9,485
-7,028
-8,148
-7,856
Income tax expense
68
27
12
100
Deferred tax recovery
-13
-2
14
21
Total income tax expense
55
25
26
121
Net loss attributed to shareholders for the period
-9,540
-7,053
-8,174
-7,977
Foreign currency translation adjustment
-950
-1,005
275
-808
Net loss and other comprehensive loss for the period
-10,490
-8,058
-7,899
-8,785
Basic EPS
-0.26
0.19
-0.257
0.26
Diluted EPS
-0.26
0.19
-0.257
0.26
Basic Average Shares
36,350,665
36,297,684
30,732,490
30,104,497
Diluted Average Shares
36,350,665
36,297,684
30,732,490
30,104,497
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net loss and othercomprehensive loss for the...-$10,490K (19.20%↑ Y/Y)US$1,301K (-34.19%↓ Y/Y)DE$182K (30.00%↑ Y/Y)CA$129K (37.23%↑ Y/Y)US$444K (-77.54%↓ Y/Y)CA$427K (354.26%↑ Y/Y)Net loss attributedto shareholders...-$9,540K (39.22%↑ Y/Y)Foreign currencytranslation adjustment-$950K (-135.02%↓ Y/Y)Net foreignexchange (gain) loss$1,245K (157.43%↑ Y/Y)Net finance income$336K (-2.04%↓ Y/Y)Recurring Non Capital$1,612K Capital Equipment$871K Net loss beforeincome taxes-$9,485K (39.32%↑ Y/Y)Total income taxexpense$55K (-14.06%↓ Y/Y)Total other (income)expenses$1,581K (186.63%↑ Y/Y)Deferred tax recovery-$13K (7.14%↑ Y/Y)Revenue (note 12)$2,483K (12.30%↑ Y/Y)Operating loss-$11,066K (19.85%↑ Y/Y)Income tax expense$68K (-12.82%↓ Y/Y)Gross profit$1,947K (20.33%↑ Y/Y)Cost of sales$536K (-9.61%↓ Y/Y)Total operatingexpenses$13,013K (-15.63%↓ Y/Y)Selling, general andadministrative$7,359K (-21.09%↓ Y/Y)Research and development$5,654K (-7.28%↓ Y/Y)

Profound Medical Corp. (PROF)

Profound Medical Corp. (PROF)